Incyte Corporation
Incyte Appoints New CEO Following Retirement of Previous CEO
Summary
Incyte Corporation announced on June 26, 2025, that Hervé Hoppenot has retired as President and Chief Executive Officer, effective the same date. Julian C. Baker, Lead Independent Director, assumed the role of Chairman of the Board. William J. Meury has been appointed as the new President and Chief Executive Officer, effective June 26, 2025. Meury will also serve on the Board. The company entered into a transition agreement with Hoppenot, who will serve as a special advisor and a non-employee consultant for up to one year following his retirement. In connection with Meury's appointment, the company amended its 2024 Inducement Stock Incentive Plan to increase the number of authorized shares and adjusted the share count provisions.
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (4)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement